Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy

References

• Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65(1):21–23. doi:10.1016/j.addr.2012.04.010
   PubMed Web of Science ®Google Scholar
• Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release. 2020;325:249–275.
   PubMed Web of Science ®Google Scholar
• Delfi M, Sartorius R, Ashrafizadeh M, et al. Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today. 2021;38.
   PubMedGoogle Scholar
• Caffery B, Lee JS, Alexander-Bryant AA. Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies. Nanomaterials. 2019;9(1):105. doi:10.3390/nano9010105
   Google Scholar
• Chang WW, Lee CH. Salmonella as an innovative therapeutic antitumor agent. Int J Mol Sci. 2014;15(8):14546–14554. doi:10.3390/ijms150814546
   PubMed Web of Science ®Google Scholar
• Panteli JT, Forbes NS. Engineered bacteria detect spatial profiles in glucose concentration within solid tumor cell masses. Biotechnol Bioeng. 2016;113(11):2474–2484. doi:10.1002/bit.26006
   PubMedGoogle Scholar
• Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol. 2003;4(9):548–556. doi:10.1016/S1470-2045(03)01194-X
   PubMed Web of Science ®Google Scholar
• Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA. 1992;268(24):3452–3455. doi:10.1001/jama.1992.03490240060037
   PubMedGoogle Scholar
• Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269(14):1829–1835. doi:10.1001/jama.1993.03500140081040
   PubMed Web of Science ®Google Scholar
• Gericke D, Engelbart K. Oncolysis by Clostridia. ii. experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. Cancer Res. 1964;24:217–221.
   PubMed Web of Science ®Google Scholar
• Singh AV, Sitti M. Targeted drug delivery and imaging using mobile milli/microrobots: a promising future towards theranostic pharmaceutical design. Curr Pharm Des. 2016;22(11):1418–1428. doi:10.2174/1381612822666151210124326
   PubMedGoogle Scholar
• Cao ZP, Liu JY. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Control Release. 2020;326:396–407. doi:10.1016/j.jconrel.2020.07.009
   PubMed Web of Science ®Google Scholar
• DeWeerdt S. BACTERIOLOGY A caring culture. Nature. 2013;504(7480):S4–S5. doi:10.1038/504S4a
   PubMedGoogle Scholar
• Prout GR. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors - comment. J Urol. 2002;167(2):893–894.
   Google Scholar
• Prout GR. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors comment. J Urol. 2017;197(2):S144–S145.
   PubMedGoogle Scholar
• Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012;4(137):137ra172. doi:10.1126/scitranslmed.3003586
   Google Scholar
• Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis. 2000;181(6):1996–2002. doi:10.1086/315497
   PubMed Web of Science ®Google Scholar
• Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142–152. doi:10.1200/JCO.2002.20.1.142
   PubMed Web of Science ®Google Scholar
• Staedtke V, Roberts NJ, Bai RY, Zhou S. Clostridium novyi-NT in cancer therapy. Genes Dis. 2016;3(2):144–152. doi:10.1016/j.gendis.2016.01.003
   PubMedGoogle Scholar
• Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004;101(42):15172. doi:10.1073/pnas.0406242101
   PubMed Web of Science ®Google Scholar
• Staedtke V, Bai R-Y, Sun W, et al. Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget. 2015;6(8):5536–5546.
   PubMedGoogle Scholar
• Gniadek TJ, Augustin L, Schottel J, Leonard A, Batist G. A phase I, dose escalation, single dose trial of oral attenuated Salmonella typhimurium containing human IL-2 in patients with metastatic gastrointestinal cancers. J Immunother. 2020;43(7):217–221. doi:10.1097/CJI.0000000000000325
   PubMedGoogle Scholar
• Flickinger JC Jr, Rodeck U, Snook AE. Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress. Vaccines. 2018;6(3):48. doi:10.3390/vaccines6030048
   Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167(11):6471–6479.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother. 2008;57(9):1301–1313. doi:10.1007/s00262-008-0463-z
   PubMed Web of Science ®Google Scholar
• Singh R, Dominiecki ME, Jaffee EM, Paterson Y. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol. 2005;175(6):3663–3673. doi:10.4049/jimmunol.175.6.3663
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Johnson ML, Cobo M, et al. JNJ-64041757 (JNJ-757), a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy in patients with NSCLC: results from two phase 1 studies. JTO Clin Res Rep. 2021;2(2):100103. doi:10.1016/j.jtocrr.2020.100103
   PubMedGoogle Scholar
• Leventhal DS, Sokolovska A, Li N, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020;11(1):2739. doi:10.1038/s41467-020-16602-0
   PubMed Web of Science ®Google Scholar
• Lee BK, Yun YH, Park K. Smart nanoparticles for drug delivery: boundaries and opportunities. Chem Eng Sci. 2015;125:158–164. doi:10.1016/j.ces.2014.06.042
   PubMed Web of Science ®Google Scholar
• Yan X, Zhou Q, Vincent M, et al. Multifunctional biohybrid magnetite microrobots for imaging-guided therapy. Sci Robot. 2017;2(12). doi:10.1126/scirobotics.aaq1155
   PubMedGoogle Scholar
• Chen F, Zang Z, Chen Z, et al. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy. Biomaterials. 2019;214:119226. doi:10.1016/j.biomaterials.2019.119226
   PubMed Web of Science ®Google Scholar
• Luo Y, Xu D, Gao X, et al. Nanoparticles conjugated with bacteria targeting tumors for precision imaging and therapy. Biochem Biophys Res Commun. 2019;514(4):1147–1153. doi:10.1016/j.bbrc.2019.05.074
   PubMed Web of Science ®Google Scholar
• Chen QW, Liu XH, Fan JX, et al. Self-mineralized photothermal bacteria hybridizing with mitochondria-targeted metal-organic frameworks for augmenting photothermal tumor therapy. Adv Funct Mater. 2020;30(14):1909806.
   Google Scholar
• Felfoul O, Mohammadi M, Taherkhani S, et al. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nat Nanotechnol. 2016;11(11):941–947. doi:10.1038/nnano.2016.137
   PubMed Web of Science ®Google Scholar
• Taherkhani S, Mohammadi M, Daoud J, Martel S, Tabrizian M. Covalent binding of nanoliposomes to the surface of magnetotactic bacteria for the synthesis of self-propelled therapeutic agents. ACS Nano. 2014;8(5):5049–5060. doi:10.1021/nn5011304
   PubMed Web of Science ®Google Scholar
• Kuru E, Hughes HV, Brown PJ, et al. In situ probing of newly synthesized peptidoglycan in live bacteria with FluorescentD-amino acids. Angew Chem Int Ed. 2012;51(50):12519–12523. doi:10.1002/anie.201206749
   PubMedGoogle Scholar
• Moreno VM, Alvarez E, Izquierdo-Barba I, Baeza A, Serrano-Lopez J, Vallet-Regi M. Bacteria as nanoparticles carrier for enhancing penetration in a tumoral matrix model. Adv Mater Interfaces. 2020;7(11):1901942.
   PubMedGoogle Scholar
• Wu M, Wu W, Duan Y, Li X, Qi G, Liu B. Photosensitizer-bacteria biohybrids promote photodynamic cancer cell ablation and intracellular protein delivery. Chem Mater. 2019;31(18):7212–7220. doi:10.1021/acs.chemmater.9b01518
   Google Scholar
• Hu Q, Wu M, Fang C, et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 2015;15(4):2732–2739. doi:10.1021/acs.nanolett.5b00570
   PubMed Web of Science ®Google Scholar
• Chen J, Shen C, Zheng C, et al. Study of properties of VEGFR2 active site and binding mode of VEGFR2 and its inhibitors. Acta Chim Sin. 2007;65(6):547–552.
   Google Scholar
• Luo CH, Huang CT, Su CH, Yeh CS. Bacteria-mediated hypoxia-specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett. 2016;16(6):3493–3499. doi:10.1021/acs.nanolett.6b00262
   PubMed Web of Science ®Google Scholar
• Wang XY, Cao ZP, Zhang MM, Meng L, Ming ZZ, Liu JY. Bioinspired oral delivery of gut microbiota by self-coating with biofilms. Sci Adv. 2020;6(26):eabb1952.
   PubMed Web of Science ®Google Scholar
• Imberti C, Zhang P, Huang H, Sadler PJ. New designs for phototherapeutic transition metal complexes. Angew Chem Int Ed Engl. 2020;59(1):61–73. doi:10.1002/anie.201905171
   PubMedGoogle Scholar
• De Windt W, Aelterman P, Verstraete W. Bioreductive deposition of palladium (0) nanoparticles on Shewanella oneidensis with catalytic activity towards reductive dechlorination of polyschlorinated biphenyls. Environ Microbiol. 2005;7(3):314–325. doi:10.1111/j.1462-2920.2005.00696.x
   PubMedGoogle Scholar
• Chen X, Shi S, Wei J, Chen M, Zheng N. Two-dimensional Pd-based nanomaterials for bioapplications. Sci Bull. 2017;62(8):579–588. doi:10.1016/j.scib.2017.02.012
   PubMedGoogle Scholar
• Wang X-N, Niu M-T, Fan J-X, Chen Q-W, Zhang X-Z. Photoelectric bacteria enhance the in situ production of tetrodotoxin for antitumor therapy. Nano Lett. 2021;21(10):4270–4279. doi:10.1021/acs.nanolett.1c00408
   PubMed Web of Science ®Google Scholar
• Yan S, Zeng X, Wang Y, Liu BF. Biomineralization of bacteria by a metal-organic framework for therapeutic delivery. Adv Healthcare Mater. 2020;9(12):e2000046. doi:10.1002/adhm.202000046
   Google Scholar
• Chu C, Su M, Zhu J, et al. Metal-organic framework nanoparticle-based biomineralization: a new strategy toward cancer treatment. Theranostics. 2019;9(11):3134–3149. doi:10.7150/thno.33539
   PubMed Web of Science ®Google Scholar
• Zheng S, Han J-W, Seong Y, Choi Y, Jin P. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella Typhimurium). Sens Actuators B Chem. 2016;224:217–224. doi:10.1016/j.snb.2015.09.034
   Google Scholar
• Traore MA, Damico CM, Behkam B. Biomanufacturing and self-propulsion dynamics of nanoscale bacteria-enabled autonomous delivery systems. Appl Phys Lett. 2014;105(17):121. doi:10.1063/1.4900641
   Google Scholar
• Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24(5):823–834. doi:10.1200/JCO.2005.03.8471
   PubMedGoogle Scholar
• Park SJ, Park SH, Cho S, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394. doi:10.1038/srep03394
   PubMed Web of Science ®Google Scholar
• Sahari A, Traore MA, Scharf BE, Behkam B. Directed transport of bacteria-based drug delivery vehicles: bacterial chemotaxis dominates particle shape. Biomed Microdevices. 2014;16(5):717–725. doi:10.1007/s10544-014-9876-y
   PubMedGoogle Scholar
• Suh S, Jo A, Traore MA, et al. Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS) enhances intratumoral transport of nanomedicine. Adv Sci. 2019;6(3):1801309.
   Google Scholar
• Uthaman S, Zheng S, Han J, et al. Preparation of engineered Salmonella Typhimurium-driven hyaluronic-acid-based microbeads with both chemotactic and biological targeting towards breast cancer cells for enhanced anticancer therapy. Adv Healthcare Mater. 2016;5(2):288–295. doi:10.1002/adhm.201500556
   Web of Science ®Google Scholar
• Kojima M, Zhang Z, Nakajima M, Ooe K, Fukuda T. Construction and evaluation of bacteria-driven liposome. Sens Actuators B Chem. 2013;183:395–400. doi:10.1016/j.snb.2013.03.127
   Google Scholar
• Zhang Z, Li Z, Yu W, Li K, Xie Z, Shi Z. Propulsion of liposomes using bacterial motors. Nanotechnology. 2013;24(18):185103. doi:10.1088/0957-4484/24/18/185103
   PubMedGoogle Scholar
• Cho S, Park SJ, Ko SY, Park JO, Park S. Development of bacteria-based microrobot using biocompatible poly(ethylene glycol). Biomed Microdevices. 2012;14(6):1019–1025. doi:10.1007/s10544-012-9704-1
   PubMedGoogle Scholar
• Rabanel JM, Hildgen P, Banquy X. Assessment of PEG on polymeric particles surface, a key step in drug carrier translation. J Control Release. 2014;185:71–87. doi:10.1016/j.jconrel.2014.04.017
   PubMed Web of Science ®Google Scholar
• Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG - a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014;192:67–81. doi:10.1016/j.jconrel.2014.06.046
   PubMed Web of Science ®Google Scholar
• Hosseinidoust Z, Mostaghaci B, Yasa O, Park BW, Singh AV, Sitti M. Bioengineered and biohybrid bacteria-based systems for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):27–44.
   PubMedGoogle Scholar
• Fox ME, Lemmon MJ, Mauchline ML, et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996;3(2):173–178.
   PubMed Web of Science ®Google Scholar
• Moese JR, Moese G. Oncolysis by clostridia. i. activity of clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res. 1964;24:212–216.
   PubMed Web of Science ®Google Scholar
• Gurbatri CR, Lia I, Vincent R, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12(530). doi:10.1126/scitranslmed.aax0876
   PubMed Web of Science ®Google Scholar
• Din MO, Danino T, Prindle A, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature. 2016;536(7614):81–85. doi:10.1038/nature18930
   PubMed Web of Science ®Google Scholar
• Fan C, Davison PA, Habgood R, et al. Chromosome-free bacterial cells are safe and programmable platforms for synthetic biology. Proc Natl Acad Sci. 2020;117(12):6752. doi:10.1073/pnas.1918859117
   PubMedGoogle Scholar
• Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13(10):605–619. doi:10.1038/nrmicro3525
   PubMed Web of Science ®Google Scholar
• Brown L, Wolf JM, Prados-Rosales R, Casadevall A. Through the wall: extracellular vesicles in gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol. 2015;13(10):620–630. doi:10.1038/nrmicro3480
   PubMed Web of Science ®Google Scholar
• Orench-Rivera N, Kuehn MJ. Environmentally controlled bacterial vesicle-mediated export. Cell Microbiol. 2016;18(11):1525–1536. doi:10.1111/cmi.12676
   PubMed Web of Science ®Google Scholar
• Clayton A, Harris CL, Court J, Mason MD, Morgan BP. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol. 2003;33(2):522–531. doi:10.1002/immu.200310028
   PubMed Web of Science ®Google Scholar
• Peng LH, Wang MZ, Chu Y, et al. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma. Sci Adv. 2020;6(27):eaba2735. doi:10.1126/sciadv.aba2735
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3–53.
   PubMedGoogle Scholar
• MacDiarmid JA, Langova V, Bailey D, et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One. 2016;11(4):e0151832. doi:10.1371/journal.pone.0151832
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Desai J, Rosenthal M, et al. A first-time-in-human Phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells. PLoS One. 2015;10(12):e0144559. doi:10.1371/journal.pone.0144559
   PubMed Web of Science ®Google Scholar
• Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7):286–298. doi:10.3109/09687688.2010.521200
   PubMed Web of Science ®Google Scholar
• Sagnella SM, Yang L, Stubbs GE, et al. Cyto-immuno-therapy for cancer: a pathway elicited by tumor-targeted, cytotoxic drug-packaged bacterially derived nanocells. Cancer Cell. 2020;37(3):354–370.e357. doi:10.1016/j.ccell.2020.02.001
   PubMed Web of Science ®Google Scholar
• Sagnella SM, Trieu J, Brahmbhatt H, et al. Targeted doxorubicin-loaded bacterially derived nano-cells for the treatment of neuroblastoma. Mol Cancer Ther. 2018;17(5):1012–1023. doi:10.1158/1535-7163.MCT-17-0738
   PubMedGoogle Scholar
• Alfaleh MA, Howard CB, Sedliarou I, et al. Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models. PLoS One. 2017;12(10):e0186137. doi:10.1371/journal.pone.0186137
   PubMedGoogle Scholar
• Whittle JR, Lickliter JD, Gan HK, et al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 2015;22(12):1889–1894. doi:10.1016/j.jocn.2015.06.005
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell. 2007;11(5):431–445. doi:10.1016/j.ccr.2007.03.012
   PubMed Web of Science ®Google Scholar
• Gujrati V, Prakash J, Malekzadeh-Najafabadi J, et al. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging. Nat Commun. 2019;10(1):1114. doi:10.1038/s41467-019-09034-y
   PubMedGoogle Scholar
• Riley PA. Melanin. Int J Biochem Cell Biol. 1997;29(11):1235–1239. doi:10.1016/S1357-2725(97)00013-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Ai K, Liu J, Deng M, He Y, Lu L. Dopamine-melanin colloidal nanospheres: an efficient near-infrared photothermal therapeutic agent for in vivo cancer therapy. Adv Mater. 2013;25(9):1353–1359. doi:10.1002/adma.201204683
   PubMed Web of Science ®Google Scholar
• Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol. 2015;15(6):375–387. doi:10.1038/nri3837
   PubMed Web of Science ®Google Scholar
• Qing S, Lyu C, Zhu L, et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020;32(47):e2002085. doi:10.1002/adma.202002085
   PubMed Web of Science ®Google Scholar
• Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014;8(2):1525–1537. doi:10.1021/nn405724x
   PubMed Web of Science ®Google Scholar
• Kim OY, Park HT, Dinh NTH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun. 2017;8(1):626. doi:10.1038/s41467-017-00729-8
   PubMed Web of Science ®Google Scholar
• Kato K, Omura H, Ishitani R, Nureki O. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu Rev Biochem. 2017;86:541–566. doi:10.1146/annurev-biochem-061516-044813
   PubMed Web of Science ®Google Scholar
• Li RZ, Liu Q. Engineered bacterial outer membrane vesicles as multifunctional delivery platforms. Front Mater. 2020;7. doi:10.3389/fmats.2020.00202
   Google Scholar
• Lee SY, Choi JH, Xu Z. Microbial cell-surface display. Trends Biotechnol. 2003;21(1):45–52. doi:10.1016/S0167-7799(02)00006-9
   PubMed Web of Science ®Google Scholar
• Gerritzen MJH, Martens DE, Wijffels RH, van der Pol L, Stork M. Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol Adv. 2017;35(5):565–574. doi:10.1016/j.biotechadv.2017.05.003
   PubMed Web of Science ®Google Scholar
• Baslé A, Rummel G, Storici P, Rosenbusch JP, Schirmer T. Crystal structure of osmoporin OmpC from E. coli at 2.0 A. J Mol Biol. 2006;362(5):933–942. doi:10.1016/j.jmb.2006.08.002
   PubMedGoogle Scholar
• Pautsch A, Schulz GE. Structure of the outer membrane protein A transmembrane domain. Nat Struct Biol. 1998;5(11):1013–1017. doi:10.1038/2983
   PubMedGoogle Scholar
• Kim JY, Doody AM, Chen DJ, et al. Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol. 2008;380(1):51–66. doi:10.1016/j.jmb.2008.03.076
   PubMed Web of Science ®Google Scholar
• Gao J, Wang S, Dong X, Wang Z. RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy via multiple tumorous targeting. Theranostics. 2021;11(7):3301–3316. doi:10.7150/thno.51988
   PubMed Web of Science ®Google Scholar
• Russo AJ, Behl B, Banerjee I, Rathinam VAK. Emerging insights into noncanonical inflammasome recognition of microbes. J Mol Biol. 2018;430(2):207–216. doi:10.1016/j.jmb.2017.10.003
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature. 2001;410(6832):1099–1103. doi:10.1038/35074106
   PubMed Web of Science ®Google Scholar
• Oliveira-Nascimento L, Massari P, Wetzler LM. The role of TLR2 in infection and immunity. Front Immunol. 2012;3:79. doi:10.3389/fimmu.2012.00079
   PubMed Web of Science ®Google Scholar
• Kuzmich NN, Sivak KV, Chubarev VN, Porozov YB, Savateeva-Lyubimova TN, Peri F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines. 2017;5(4):34.
   PubMed Web of Science ®Google Scholar
• Carleton HA, Lara-Tejero M, Liu X, Galán JE. Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery. Nat Commun. 2013;4(1):1590. doi:10.1038/ncomms2594
   PubMedGoogle Scholar
• Huang W, Shu C, Hua L, et al. Modified bacterial outer membrane vesicles induce autoantibodies for tumor therapy. Acta Biomater. 2020;108:300–312. doi:10.1016/j.actbio.2020.03.030
   PubMed Web of Science ®Google Scholar
• Wang S, Huang W, Li K, et al. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor. Int J Nanomedicine. 2017;12:6813–6825. doi:10.2147/IJN.S143264
   PubMed Web of Science ®Google Scholar
• Zakeri B, Fierer JO, Celik E, et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A. 2012;109(12):E690–E697. doi:10.1073/pnas.1115485109
   PubMed Web of Science ®Google Scholar
• Veggiani G, Nakamura T, Brenner MD, et al. Programmable polyproteams built using twin peptide superglues. Proc Natl Acad Sci U S A. 2016;113(5):1202–1207. doi:10.1073/pnas.1519214113
   PubMed Web of Science ®Google Scholar
• Cheng K, Zhao R, Li Y, et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology. Nat Commun. 2021;12(1):2041. doi:10.1038/s41467-021-22308-8
   PubMed Web of Science ®Google Scholar
• Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2019;29(11):3766. doi:10.1016/j.celrep.2019.11.113
   PubMedGoogle Scholar
• Li Y, Zhao R, Cheng K, et al. Bacterial outer membrane vesicles presenting programmed death 1 for improved cancer immunotherapy via immune activation and checkpoint Inhibition. ACS Nano. 2020;14(12):16698–16711. doi:10.1021/acsnano.0c03776
   PubMed Web of Science ®Google Scholar
• Wang D, Liu C, You S, et al. Bacterial vesicle-cancer cell hybrid membrane-coated nanoparticles for tumor specific immune activation and photothermal therapy. ACS Appl Mater Interfaces. 2020;12(37):41138–41147. doi:10.1021/acsami.0c13169
   PubMed Web of Science ®Google Scholar
• Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol. 2010;64(1):163–184. doi:10.1146/annurev.micro.091208.073413
   PubMed Web of Science ®Google Scholar
• Chen Q, Bai H, Wu W, et al. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention. Nano Lett. 2020;20(1):11–21. doi:10.1021/acs.nanolett.9b02182
   PubMed Web of Science ®Google Scholar